<DOC>
	<DOC>NCT00171743</DOC>
	<brief_summary>The purpose of this study is to determine whether the switch from tacrolimus to cyclosporine microemulsion benefits post-transplant diabetes management (in terms of glycogenic control and insulin dosage) in stable liver transplant recipients.</brief_summary>
	<brief_title>Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>At least 4 months posttransplant Patients in treatment with tacrolimus Posttransplant diabetes treated with insulin for at least one month Exclusion Criteria Known hypersensitivity to cyclosporine microemulsion Investigational drug within 60 days before baseline or during the study Patients who cannot comply with the study requirements Other protocoldefined exclusion criteria applied</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Adults</keyword>
	<keyword>Post transplant diabetes</keyword>
</DOC>